Published in Curr Opin Endocrinol Diabetes Obes on June 01, 2007
Osteoporosis in men. Endocr Rev (2008) 1.80
Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst (2010) 1.63
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol (2009) 1.44
[Not Available]. Can Urol Assoc J (2014) 1.38
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther (2010) 1.10
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Treatment of osteoporosis in men. Bone (2012) 1.06
Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer (2012) 0.99
Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone. Hum Gene Ther (2013) 0.96
Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol (2009) 0.95
Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology (2014) 0.94
Hematological changes during androgen deprivation therapy. Asian J Androl (2012) 0.91
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Can Urol Assoc J (2010) 0.89
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One (2014) 0.88
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol (2011) 0.87
Osteoporosis in men. Nat Rev Endocrinol (2013) 0.85
Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer. Oncol Hematol Rev (2014) 0.85
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res (2011) 0.84
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
Male osteoporosis: A review. World J Orthop (2012) 0.83
Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian J Urol (2009) 0.82
Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol (2014) 0.81
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res (2010) 0.81
Connecting the Lines between Hypogonadism and Atherosclerosis. Int J Endocrinol (2012) 0.81
Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol (2009) 0.79
The relationship between BPAQ-derived physical activity and bone density of middle-aged and older men. Osteoporos Int (2014) 0.79
Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging (2011) 0.79
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2009) 0.77
High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl (2010) 0.76
Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study. Drugs Real World Outcomes (2016) 0.75
Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. Urol Pract (2015) 0.75
Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press) (2015) 0.75
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA (2015) 0.75
Risk stratification in the hormonal treatment of patients with prostate cancer. Ther Adv Med Oncol (2009) 0.75
Androgen actions on endothelium functions and cardiovascular diseases. J Geriatr Cardiol (2016) 0.75
Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis (2014) 0.75
Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males. Springerplus (2016) 0.75
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World J Urol (2012) 0.75
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39
Osteoclast differentiation and activation. Nature (2003) 18.59
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA (2002) 18.43
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 9.95
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 6.88
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Osteoporosis after orchiectomy for prostate cancer. J Urol (1997) 4.32
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol (2005) 2.87
Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 2.85
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol (1997) 2.75
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Noncancer deaths in white adult cancer patients. J Natl Cancer Inst (1993) 2.28
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res (1997) 2.03
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab (2004) 2.01
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology (2004) 2.01
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol (2006) 1.89
Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol (2000) 1.85
Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol (2001) 1.83
Testosterone therapy in glucocorticoid-treated men. Arch Intern Med (1996) 1.82
Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol (1999) 1.80
Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med (1984) 1.75
Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab (1997) 1.73
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest (1997) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int (2006) 1.58
Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol (2002) 1.58
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control (1998) 1.54
Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res (1998) 1.46
Testosterone, body composition and aging. J Endocrinol Invest (1999) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (1997) 1.32
Osteoporosis in men. J Clin Endocrinol Metab (1999) 1.29
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden) Cancer Causes Control (1998) 1.25
Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab (2001) 1.25
Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int (2000) 1.18
Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology (1986) 1.17
The structural basis of bone fragility in men. Bone (1999) 1.17
Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism (1990) 1.13
Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol (2004) 1.12
Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci U S A (1994) 1.09
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int (1995) 1.07
Osteoporosis in men. Endocrinol Metab Clin North Am (1998) 1.04
Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab (2000) 1.03
Hip fractures in men with prostate cancer treated with orchiectomy. J Urol (2004) 0.93
Raloxifene. Drugs Aging (1998) 0.84
Hormonal regulation of circulating C-reactive protein in men. Clin Chem (2005) 0.82
The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab (2002) 0.81
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol (2004) 0.87